(Boursier.com) — seagen climbed 10% on Wall Street towards $162, while according to the Wall Street Journal, the American pharmaceutical giant Merck would have studied a takeover of the biotechnology firm. The WSJ cites sources familiar with the matter. Talks have been going on for some time, but no deal is imminent, according to the newspaper. Seagen currently weighs nearly 30 billion dollars on Wall Street, against 215 billion dollars for Merck & Co. The WSJ also indicates that other suitors would also evaluate the Seagen file. Regarding a possible Merck deal, the newspaper adds that difficulties could be encountered with regulators. It would thus be possible that the discussions only lead to a marketing agreement.
©2022 Boursier.com